SAKAR

Sakar Healthcare Limited

Listed company · ISIN INE732S01012 · NSE EQ · FV ₹10
Last price
₹980
+3.70%today
What this company does

Sakar Healthcare Limited is a listed company. It booked ₹87 cr of revenue in its latest quarter (Q2 FY27) and kept 12.9% of sales as profit.

In the report:
62out of 100
Equitytale Health Score
Mixed

Healthier than 62% of listed companies we score, on all six measures of filed financials. Each measure is ranked against the 1,198–2,932 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
46

At close. Not part of the score.

Profitability & returns63

How much profit it earns on the money it employs

Balance sheet60

How much it owes, and whether earnings cover the interest

Cash quality57

Whether reported profit actually arrives as cash

Growth & consistency86

Whether sales and profit have grown, and how steadily

Valuation18

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Is this company doing well?
not investment advice
Looks broadly healthy
Strengths
✓ Makes a profit
✓ Sales up 52% vs last year
✓ Profit up 149% vs last year
✓ Promoters hold 52%
✓ No promoter shares pledged
✓ Turns profit into real cash
Watch-outs
None flagged from our data

What if I invest in SAKAR?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 15% a year, it would become
₹26.30 lakh

The slider starts at 15%, taken from this company's own revenue trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹980▲ +3.70%
latest close · 2026-11-04
1-year return
+448.3%
52-wk low ₹10352-wk high ₹1,230
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio48.2High
LowAverageHigh
P/B ratio6.30High
Below bookModerateHigh
EV / EBITDA22.6High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity13.1%Fair
WeakFairStrong ▸15%
Return on capital18.2%Strong
WeakFairStrong
Net margin12.9%Decent
ThinDecentStrong
EBITDA margin28.2%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.13Comfortable
LowModerateHigh ▸1
Interest cover9.0×Strong
RiskyOkayStrong ▸5×
Current ratio1.34Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹2,179 cr
Book value
₹156
EPS
₹5.08
latest quarter
Net debt
₹46 cr
owes more than its cash
Enterprise value
₹2,225 cr
EBITDA
₹99 cr
annualised
EBIT
₹72 cr
annualised
Operating margin
20.6%
Return on assets
8.8%
Earnings yield
2.07%
P/S
6.23
Sales / share
₹157.2
Tax rate
29.4%
Face value
₹10
Shares
2.2 cr
Working capital
₹41 cr
Current assets
₹161 cr
Current liabilities
₹120 cr
Delivery %
42.1%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.

Worth vs price · from the FY 2025 report & filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹142–₹148, midpoint ₹145

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q2 FY27 (consolidated)
Revenue from Operations₹87 cr
Other Income₹28.1 L
Total Income₹88 cr
Cost of Materials₹49 cr
Purchases of Stock-in-Trade₹0 cr
Inventory Change (±)₹-3 cr
Employee Benefit Expense₹10 cr
Finance Costs₹2 cr
Depreciation & Amortisation₹7 cr
Other Expenses₹8 cr
Total Expenses₹72 cr
Profit before Tax₹16 cr
Tax Expense₹5 cr
Net Profit₹11 cr
Net margin on total income12.9%
Where the money goes · Q2 FY27
% of total income
Materials + stock-in-trade₹46 cr52.2%
Employee benefit expense₹10 cr11.1%
Finance costs₹2 cr2.3%
Depreciation & amortisation₹7 cr7.5%
Other expenses₹8 cr8.6%
Tax expense₹5 cr5.4%
Profit for the period₹11 cr12.9%
Total income ₹88 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ4 FY26Q1 FY27Q2 FY27
Revenue71 cr73 cr87 cr
Total income71 cr75 cr88 cr
Expenses53 cr60 cr72 cr
Profit before tax18 cr15 cr16 cr
Tax7 cr4 cr5 cr
Net profit (owners' share)11 cr10 cr11 cr
Net margin (owners' share, on revenue)15.5%14.1%12.9%
EPS (₹)4.964.625.08
YoY (latest quarter): total income +49.2% · net profit +149.1%
Balance sheet & cash flow · as of Sep 2026
Low debt
Total assets
₹516 cr
Shareholder equity
₹346 cr
parent shareholders
Total debt
₹46 cr
Cash
₹4.8 L
Cash flow · H1 FY27
Operating
₹23 cr
Investing
₹-22 cr
Financing
₹-1 cr
Who owns it · 2026-09-30
No pledge
Promoter
51.7%
FII / Foreign
12.3%
DII / Domestic
11.9%
Retail / others
24.0%
Promoter stake down 1.4% over the last 12 quarters.
Smart-money activity
Insider trades
SoldRita S. Shah · Promoter45,000 · ₹4.5 cr28 Oct 26
SoldAarsh S. Shah · Promoter5,100 · ₹51.2 L3 Sep 26
SoldAarsh S. Shah · Promoter35,000 · ₹3.5 cr2 Sep 26
Bulk / block deals
BoughtSTELLAR WEALTH PARTNERS INDIA FUND I LP · NSE1.95 L @ ₹664.5815 May 26
BoughtRATHOD SAAJAN S · NSE1.15 L @ ₹133.5517 May 22
SoldRATHOD SAAJAN S · NSE68,692 @ ₹138.4717 May 22
Stake changes
BoughtSanjay S. Shah along with PAC · promoter→ 45.60% · 1.00 L27 Dec 24
BoughtAarsh Sanjay Shah · promoter→ 6.41% · 1.00 L27 Dec 24
SoldCobra India (Mauritius) Limited→ 6.76% · 30,42924 Jan 24
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 22 Sep 2026
See the official result
1
Adoption of the Audited Standalone & Consolidated Financial Statements of the Company for the financial year ended 31st March, 2026, the Reports of the Board of Directors and Auditors thereon.
Backed by 100% of shareholders other than promotersneeded 50%
1.64 L votes for, 2 against · 0% of mutual funds and other big investors said no
2
Re-appointment of Ms. Visalakshi Chandramouli, liable to retire by rotation and being eligible, offers herself for re-appointment.
Backed by 84% of shareholders other than promotersneeded 50%
1.38 L votes for, 26,604 against · 100% of mutual funds and other big investors said no
3
Ratification of Remuneration of Cost Auditors of the Company.
Backed by 100% of shareholders other than promotersneeded 50%
1.64 L votes for, 2 against · 0% of mutual funds and other big investors said no
4
Appointment of M/s. Kashyap R Mehta & Partners, Practising Company Secretaries, a Peer Reviewed firm as Secretarial Auditors of the Company for 5 consecutive years
Backed by 100% of shareholders other than promotersneeded 50%
1.64 L votes for, 2 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 4 named members
owning 51.7% between them · as of 2026-09-30
Sanjay S Shah44.98%
Shah Aarsh5.60%
Ritaben Shah1.10%
Shah Ayushi0.02%
Business done with them
FY2026 · 1 of the group
The company paid ₹2 cr to companies in the promoter group last year — about 0.7% of its ₹252 cr revenue.
Aarsh Shah
Other payments to them · Remuneration and Loan
also owns 5.60% of the company
₹2 cr
company paid

The company also transacted with 2 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹9 cr raised in Jun 2025 by selling shares to selected investors

As of Sep 2025, the company says it has spent 100% of what it set aside.

Capital expenditure for Procurement of Lipid Complex Injections Machinery and Equipments/Utilities with electrification for Oncology unit
100%
₹7 cr of ₹7 cr
₹6 cr raised in Dec 2024 by selling shares to selected investors

As of Mar 2025, the company says it has spent 100% of what it set aside.

Repayment/ prepayment of all or a portion of certain borrowings from State Bank of India availed by our Company
100%
₹1 cr of ₹1 cr
Capital expenditure for Procurement of Lipid Complex Injections Machinery and Equipments/Utilities with electrification for Oncology unit
100%
₹4 cr of ₹4 cr
General corporate purposes
100%
₹40 L of ₹40 L

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.